Tecan Group AG / Tecan successfully completes OEM development of Dako Omnis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Männedorf, Switzerland, June 7, 2013 - The Tecan Group (SIX Swiss Exchange: TECN) announced today that it has successfully completed the OEM development of the Dako Omnis. In May 2011, Tecan signed a major OEM agreement with Dako, an Agilent Technologies Company (NYSE: A) and worldwide provider of cancer diagnostics, for the development and supply of an advanced staining platform. Formerly the development program was referred to by Tecan as P16. The Dako Omnis instrument, co-developed with Dako and manufactured by Tecan, comprises hardware and software and sets new standards in automated tissue-based cancer diagnostics.
Tecan CEO David Martyr commented: "We are delighted that we successfully completed the development of the Dako Omnis as planned and only two years after signing the agreement. As communicated before, we expect sales volumes for Tecan from the supply of the Dako Omnis to accelerate from the second half of this year with a substantial contribution to our sales growth from 2014 onwards."
About Tecan
Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2012, Tecan generated sales of CHF 391 million (USD 416 million; EUR 323 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Braendle
Head of Corporate Communications & Investor Relations
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com (mailto:investor@tecan.com)
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Tecan Group AG via Thomson Reuters ONE
--- End of Message ---
Tecan Group AG
Seestrasse 103 Männedorf Switzerland
ISIN: CH0012100191;
